CCM
AMPH icon

Coldstream Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Coldstream Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-334
Closed -$9.68K – 1212
2025
Q1 		$9.68K Buy
+334
New +$10.7K ﹤0.01% 2391

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Coldstream Capital Management's AMPH Position: Q2 2025 in Review

Coldstream Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 334 shares — an estimated $9.68K sold.

Coldstream Capital Management first reported a position in AMPH in Q1 2025 and held it in 1 quarter. The position peaked at $9.68K in Q1 2025. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • Coldstream Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 334 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $9.68K.
  • Coldstream Capital Management first reported a position in Amphastar Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Amphastar Pharmaceuticals position peaked at $9.68K in Q1 2025.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.